Madrid, August 1, 2023 - The cardiovascular polypill developed by the Spanish National Center for Cardiovascular Research (CNIC) and Ferrer has just been included by the World Health Organization (WHO) in the list of essential medicines1.
This cardiovascular polypill includes three active ingredients (acetylsalicylic acid, ramipril and atorvastatin) and has been shown to be effective in the prevention of cardiovascular events after a heart attack, reducing mortality from cardiovascular causes by 33%. This was evidenced by the SECURE2 study, the results of which were published in August 2022, in The New England Journal of Medicine3 (NEJM).
"The results of SECURE revealed, for the first time, that the cardiovascular polypill developed by the CNIC and Ferrer achieves clinically relevant reductions in recurrent cardiovascular events in patients who have suffered a myocardial infarction," said Dr. Valentín Fuster, principal investigator of the study, Director General of the CNIC, Director of the Mount Sinai Heart and Medical Director of Mount Sinai Hospital. of New York.
He adds: "Adherence to treatment after an acute myocardial infarction is essential for effective secondary prevention. This cardiovascular polypill, being a strategy that combines three of the basal treatments in this type of patient, has demonstrated its value, since increased adherence means that patients are being treated for longer and, thanks to this, have a lower risk of suffering cardiovascular events".
Lists of essential medicines are registries of medicines that the WHO considers minimum requirements that every health system must have available, which are updated every two years. These lists are internationally recognized for countries' health systems, helping them prioritize effective and affordable medicines.
As stated in the WHO report, "essential medicines are those that meet the priority health care needs of a population. They are intended to be available in functioning health systems at all times, in appropriate dosage forms, of assured quality, and at prices that individuals and health systems can afford."
According to Oscar Pérez, Chief Marketing, Market Access and Business Development Officer at Ferrer, "the reduction in cardiovascular mortality by 33% demonstrates the efficacy of treatment with Trinomia4 compared to standard treatment. The inclusion of this therapeutic solution in the WHO list of essential medicines ratifies our purpose to generate a positive impact on society and is an important step in our mission to provide significant and differential value to people with cardiovascular disease".
Dr. Fuster also highlights that "this cardiovascular polypill could become an integral part of strategies to prevent cardiovascular events in patients who have suffered a heart attack and who are currently being treated with the monocomponents separately. This approach has the potential to reduce the risk of recurrent disease and cardiovascular death."
Currently, the cardiovascular polypill developed by the CNIC and Ferrer is marketed in 25 countries and the feasibility of expanding its distribution to additional territories is being analyzed, the United States being one of them.
References:
- https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2023.02
- SECURE Study - https://www.cnic.es/es/investigacion/clinica
- Polypill Strategy in Secondary Cardiovascular Prevention Castellano JM, Fuster V et al. New England Journal of Medicine (NEJM). Aug. 2022 (see: https://www.nejm.org/doi/full/10.1056/NEJMoa2208275)
- Trinomia® data sheet: TRINOMIA TECHNICAL SHEET 100 MG/40 MG/10 MG HARD CAPSULES (aemps.es) (consult: https://cima.aemps.es/cima/dochtml/ft/81774/FT_81774.html)
